Clinical experience with fluticasone propionate in asthma: A meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less

Respiratory Medicine

Volumn 92, Issue 1, 1998, Pages 95-104

  Barnes, N C ^a   Hallett, C ^b   Harris, T A J ^b  

^a LONDON CHEST HOSPITAL   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; BECLOMETASONE DIPROPIONATE; BUDESONIDE; FLUTICASONE PROPIONATE; HYDROCORTISONE;

ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYDROCORTISONE BLOOD LEVEL; INHALATIONAL DRUG ADMINISTRATION; META ANALYSIS; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL;

EID: 0031888153     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(98)90039-7     Document Type: Article

References (31)

1. National Heart, Lung and Blood Institute. International consensus report on diagnosis and treatment of asthma. Eur Respir J 1992; 5: 601-641.
2. British Thoracic Society. Guidelines for management of asthma. Thorax 1993; 48 (Suppl): S1-S24.
3. The British Guidelines on Asthma Management. 1995 Review and Position Statement. Thorax 1997; 52 (Suppl. 1).
4. Brown PH, Blundell G, Greening AP, Crompton GK. Hypothalamo-pituitary-adrenal axis suppression in asthmatics inhaling high dose corticosteroids. Respir Med 1991; 85: 501-510.
5. Barnes NC. The therapeutic efficacy and side effects of inhaled steroids. Int Monitor 1992; 3: 1-4.
6. Geddes D. Inhaled corticosteroids: benefits and risks. Thorax 1992; 47: 404-406.
7. Phillips GH. Structure-activity relationships of topically active steroids: the selection of fluticasone propionate. Respir Med 1990; 84 (Suppl. A): 19-23.
8. Harding SM. The human pharmacology of fluticasone propionate. Respir Med 1990; 84 (Suppl. A): 25-29.
9. Ryrfeldt A, Andersson P, Edshaker S et al. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis 1982; 63 (Suppl. 122): 86-95.
10. Svendsen UG. Fluticasone propionate (a new inhaled steroid): clinical development in mild to moderate adult asthmatics. Eur Respir J 1990; 3 (Suppl. 10): 250s, S924.
11. Bye A. The oral systemic availability of fluticasone propionate in man - preliminary data. Br J Clin Pharmacol 1993; 36: 136.
12. Dahl R, Lundback B, Malo JL et al. A dose- ranging study of fluticasone propionate in adult patients with moderate asthma. Chest 1993; 104: 1352-1358.
13. Langdon CG, Capsey LJ, on behalf of a UK Study Group. Fluticasone propionate and budesonide in adult asthmatics: a comparison using dry-powder inhaler devices. Br J Clin Res 1994; 5: 85-89.
14. Langdon CG, Thompson J, on behalf of a UK study group. A multicentre study to compare the efficacy and safety of inhaled fluticasone propionate and budesonide via metered-dose inhalers in adults with mild-to-moderate asthma. Br J Clin Res 1994; 5: 73-84.
15. Connolly A, on behalf of a UK Study Group. A comparison of fluticasone propionate 100μg twice daily with budesonide 200μg twice daily via their respective powder devices in the treatment of mild asthma. Eur J Clin Res 1995; 7: 15-29.
16. Backman R, Pickering CA, Baumgarten C, Huskisson SC. Fluticasone propionate Diskus® 250 μg bd compared with budesonide Turbohaler® 600 μg bd in adult asthmatics. JACI 1996, 97: A267.
17. Williams J. Efficacy and ease of use of the fluticasone propionate multi-dose powder inhaler compared with the budesonide reservoir powder device in asthmatic children. Eur Respir J 1995; 8 (Suppl. 19): 469s, P2313.
18. Ringdal N, Swinburn P, Backman R et al. A blinded comparison of fluticasone propionate with budesonide in adult patients with moderate-to-severe asthma. Mediators Inflamm. 1996; 5: 382-389.
19. Steinmetz K-O, Trautmann M. Efficacy of fluticasone propionate (0-5 mg daily) via MDI and budesonide (1.2mg daily) via Turbuhaler® in the treatment of steroid-naive asthmatics. Am J Respir Crit Care Med 1996; 153: A338.
20. Barnes NC, Marone G, Di Maria GU, Visser S, Utama I, Payne SL, on behalf of an International Study Group. A comparison of fluticasone propionate, 1 mg daily, with beclomethasone dipropionate, 2 mg daily, in the treatment of severe asthma. Eur Respir J 1993; 6: 877-884.
21. Gustafsson P, Tsanakas J, Gold M, Primhak, Radford M, Gillies E. Comparison of the efficacy and safety of inhaled fluticasone propionate 200 μg/day with inhaled beclomethasone dipropionate 400/μ/day in mild and moderate asthma. Arch Dis Childhood 1993; 69: 206-211.
22. -1) administered by pressurised inhaler. Respir Med 1993; 87: 609-620.
23. Leblanc P, Mink S, Keistinen T, Saarlainen PA, Ringdal N, Payne SL. A comparison of fluticasone propionate 200 μg/day with beclomethasone dipropionate 400/μg/day in adult asthma. Allergy 1994; 49: 380-385.
24. Bootsma GP, Dekhuijzen PNR, Festen J, Mulder PGH, van Herwaarden CLA. Comparison of fluticasone propionate and beclomethasone dipropionate on direct and indirect measurements of bronchial hyper-responsiveness. ATS 1995; B24: Poster A41.
25. Pauwels RA, Demedts MG, Yernault JC, Geusens, Roosens WA. Comparison of long-term safety and efficacy of fluticasone propionate and beclomethasone dipropionate in combination with salmeterol in patients with moderate to severe asthma. Am J Resp Crit Care Med 1995; 151 (4 suppl): A276 (Abstract).
26. Fleiss JL. Statistical Methods in Medical Research 1993; 2: 121-145.
27. Grahnén A, S-Å Eckernäs, Brundin RM, Ling-Andersson A. An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers. Br J Clin Pharmacol 1994; 38: 521-525.
28. Grove A, Allam C, McFarlane LC, McPhate G, Jackson CM, Lipworth BJ. A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects. Br J Clin Pharmacol 1994; 38: 527-532.
29. Lonnebo A, Grahnen A, Jansson B, Brundin RM, Ling-Andersson A, Eckernas SA. An assessment of systemic effects of single and repeated doses of inhaled fluticasone propionate and inhaled budesonide in healthy volunteers. Ew J Clin Pharm 1996; 49: 459-463.
30. Falcoz C, Mackie AE, Horton J et al. Pharmacokinet-ics of fluticasone propionate inhaled from the Diskhaler® and Diskus® powder devices in asthmatic patients. BPJ December 1996: P250, P249
31. Thorsson L, Edsbäcker S, Conradson T-B. Lung depo-sition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J 1994; 7: 1839-1844.